BioCentury | Dec 14, 2018
Financial News

Allen Insitute's immunology division launches with $125M, Lilly vet and five partners

...approaches for diagnostics and therapeutics. Its other two research divisions for brain science and for cell science...
BioCentury | Dec 13, 2018
Preclinical News

Allen Institute's immunology division launches with $125M, Lilly vet and five partners

...approaches for diagnostics and therapeutics. Its other two research divisions for brain science and for cell science...
BioCentury | Aug 24, 2017
Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
BioCentury | Jun 22, 2017
Translation in Brief

TERS talk

A UCSD group has added "transmissible ER stress (TERS)" to the list of cancer's survival strategies. In a study published this month in Science Signaling , the group showed cancer cells undergoing ER stress send soluble...
BioCentury | Jun 8, 2017
Finance

The bio-tech bridge

...include the Allen Institute for Brain Science, created in 2003, and the Allen Institute for Cell Science...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...important in all immunotherapies, including CAR T cells,” said Julianne Smith, VP of CAR T cell science...
BioCentury | Mar 9, 2017
Translation in Brief

To screen and protect

A Science Translational Medicine study has established a quantitative metric of drug cardiotoxicity in human-derived cardiomyocytes, and identified insulin-based strategies to alleviate the cardiotoxicity of certain tyrosine kinase inhibitors (TKIs). Study leader Joseph Wu said...
BioCentury | Nov 17, 2016
Translation in Brief

Editing hemoglobin

Three independent teams have demonstrated three different ways of using CRISPR to treat sickle cell disease, paving the way for correcting genetic mutations in a disease where the only long-term therapeutic option is blood transplants...
BioCentury | Oct 6, 2016
Targets & Mechanisms

Seeking cysteines

In settling the question of how Biogen Inc. 's Tecfidera dimethyl fumarate (DMF) acts in multiple sclerosis, a Scripps team has identified PKCθ as a key driver, sitting atop an NF-κB pathway to immunosuppression. The...
Items per page:
1 - 10 of 151
BioCentury | Dec 14, 2018
Financial News

Allen Insitute's immunology division launches with $125M, Lilly vet and five partners

...approaches for diagnostics and therapeutics. Its other two research divisions for brain science and for cell science...
BioCentury | Dec 13, 2018
Preclinical News

Allen Institute's immunology division launches with $125M, Lilly vet and five partners

...approaches for diagnostics and therapeutics. Its other two research divisions for brain science and for cell science...
BioCentury | Aug 24, 2017
Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
BioCentury | Jun 22, 2017
Translation in Brief

TERS talk

A UCSD group has added "transmissible ER stress (TERS)" to the list of cancer's survival strategies. In a study published this month in Science Signaling , the group showed cancer cells undergoing ER stress send soluble...
BioCentury | Jun 8, 2017
Finance

The bio-tech bridge

...include the Allen Institute for Brain Science, created in 2003, and the Allen Institute for Cell Science...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...important in all immunotherapies, including CAR T cells,” said Julianne Smith, VP of CAR T cell science...
BioCentury | Mar 9, 2017
Translation in Brief

To screen and protect

A Science Translational Medicine study has established a quantitative metric of drug cardiotoxicity in human-derived cardiomyocytes, and identified insulin-based strategies to alleviate the cardiotoxicity of certain tyrosine kinase inhibitors (TKIs). Study leader Joseph Wu said...
BioCentury | Nov 17, 2016
Translation in Brief

Editing hemoglobin

Three independent teams have demonstrated three different ways of using CRISPR to treat sickle cell disease, paving the way for correcting genetic mutations in a disease where the only long-term therapeutic option is blood transplants...
BioCentury | Oct 6, 2016
Targets & Mechanisms

Seeking cysteines

In settling the question of how Biogen Inc. 's Tecfidera dimethyl fumarate (DMF) acts in multiple sclerosis, a Scripps team has identified PKCθ as a key driver, sitting atop an NF-κB pathway to immunosuppression. The...
Items per page:
1 - 10 of 151